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Neutralizing antibodies (inhibitors) to replacement factor VIII (FVIII, either plasma derived or recombinant) impair the effective management of hemophilia A 1 . Individuals with hemophilia A due to major deletions of the FVIII gene (F8) lack antigenically cross-reactive material in their plasma ("CRMnegative"), and the prevalence of inhibitors in these individuals may be as high as 90%. Conversely, individuals with hemophilia A caused by F8 missense mutations are CRM-positive, and their overall prevalence of inhibitors is <10% (ref. 2) . Individuals with the F8 intron 22 inversion (found in ~50% of individuals with severe hemophilia A) have been grouped with the former on the basis of their genetic defect and CRM-negative status. However, only ~20% of these individuals develop inhibitors 3 .
Here we demonstrate that the levels of F8 mRNA and intracellular FVIII protein in B lymphoblastoid cells and liver biopsies from individuals with the intron 22 inversion are comparable to those in healthy controls. These results support the hypothesis that most individuals with the intron 22 inversion are tolerized to FVIII and thus do not develop inhibitors. Furthermore, we developed a new pharmacogenetic algorithm that permits the stratification of inhibitor risk for individuals and subpopulations by predicting the immunogenicity of replacement FVIII using, as input, the number of putative T cell epitopes in the infused protein and the competence of major histocompatibility complex class II molecules to present such epitopes. This algorithm showed statistically significant accuracy in predicting the presence of inhibitors in 25 unrelated individuals with the intron 22 inversion.
Recombinant and plasma-derived FVIII proteins are used as replacement therapies to treat individuals with hemophilia A who have mutations in F8. With improvements in technology and strict adherence to the regulatory requirements for the production of biologics, the increased use of recombinant FVIII proteins has minimized productrelated risk factors for immunogenicity, that is, those associated with variations in the manufacturing process. Clinical studies have provided evidence that genetic variables, particularly the type of F8 mutation causing hemophilia A, are important determinants of the immunogenicity of the infused FVIII (ref.
3) ( Fig. 1a) . Synthesis of the FVIII polypeptide chain is necessary for inducing central tolerance; for example, individuals with hemophilia A who have a missense mutation in F8 have a <10% lifetime prevalence of inhibitors, whereas the prevalence of inhibitors in individuals with large gene deletions can be as high as 88% (ref. 2) . Notably, individuals with the F8 intron 22 inversion (I22I) have a much lower than expected prevalence of inhibitors, given that this mutation has a major effect on gene structure and the clinical observation that these individuals have CRMnegative plasma. A recent systematic review and meta-analysis of data from 5,385 subjects with severe hemophilia A showed that individuals with large F8 deletions involving more than one exon developed inhibitors far more often than did individuals with the I22I mutation (pooled odds ratio 3.6, 95% confidence interval 2.3-5.7) (ref. 3 ).
On the basis of the structure of the intron 22 inversion, we hypothesized that individuals with I22I would produce and translate two F8 exon-containing mRNAs (here referred to as F8 I22I and F8 B ), which together comprise all 26 F8 exons of the full-length mRNA (F8 FL ).
Endogenous factor VIII synthesis from the intron 22inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A Furthermore, F8 I22I and F8 B would together express the entire primary amino acid sequence of FVIII as two non-secreted polypeptide chains, FVIII I22I and FVIII B ( Fig. 1b and Supplementary Fig. 1 ).
To explore this possibility, we used a quantitative RT-PCR-based assay to detect and estimate the levels of F8 exon-containing mRNAs in Epstein-Barr virus-immortalized B lymphoblastoid cells obtained from a normal subject (Nor) and from a subject with hemophilia A with the I22I mutation (Inv). We used three sets of primers ( Supplementary Table 1 ) to amplify exonic regions upstream and downstream of intron 22 (exons 1-22 and 23-26) and across the junction between exons 22 and 23. All three of these primer pairs are expected to detect the F8 FL transcript that occurs in Nor cells. However, because patients with the I22I mutation express the F8 I22I and F8 B transcripts, but not F8 FL , only the primer pairs upstream or 
Median fluorescence (arbitary units) downstream of intron 22 detect transcripts encoded by the mutant F8 locus. As expected, the primer set designed to generate cDNAs spanning this junction detected F8 FL transcripts in Nor but not in Inv cells, whereas the primer sets designed to generate cDNAs spanning exons 1-22 and exons 23-26 detected comparable levels of F8 FL , F8 I22I and F8 B mRNAs in Nor (comprising F8 FL and F8 B ) and Inv (comprising F8 I22I and F8 B ) cells (Fig. 1c) . The intrachromosomal homologous recombination that gives rise to the I22I mutation can involve one of two ~10-kilobase segments of Xq28 chromosomal DNA; of these, recombination at the distal of the two segments is more common 4 and was detected in the subject that donated the Inv cells ( Supplementary Fig. 2 ).
We predicted that the mRNA sequence of F8 I22I obtained from Inv cells would yield a translated polypeptide containing 2,159 amino acid residues, of which the 2,143 N-terminal residues would be identical to those of the wild-type FVIII protein (FVIII FL ). The C-terminal 16 amino acids of FVIII I22I are predicted to be derived from a novel exon 23, termed exon 23 c . We bidirectionally sequenced overlapping cDNAs that spanned the entire FVIII FL and FVIII B transcripts in the RNA isolated from the Nor cells, as well as the entire FVIII I22I and FVIII B transcripts in the RNA isolated from the Inv cells, and used these sequences to determine the predicted amino acid sequence of the resultant polypeptides. The alignments of the nucleotide and amino acid sequences ( Fig. 1d) show that the F8 I22I transcript encodes a polypeptide with 16 non-FVIII amino acid residues at its C terminus (FVIII I22I ). Similarly, the first eight residues of FVIII B are not found in FVIII FL (Supplementary Fig. 3) . Nonetheless, the polypeptides FVIII I22I and FVIII B together comprise the entire primary sequence of F8 FL (Supplementary Fig. 3) .
To demonstrate that the I22-inverted F8 gene does indeed synthesize the predicted protein products, FVIII I22I and FVIII B , we used a human FVIII-specific polyclonal antibody to immunoprecipitate FVIII protein from Nor and Inv cells. For each sample, we performed mass spectrometric analysis to confirm the identity of the bands that aligned with purified FVIII in an SDS-PAGE gel (Fig. 1e) . These data demonstrate that both Nor and Inv cells synthesize FVIII polypeptides. We also identified the FVIII I22I and FVIII B polypeptides in Inv cells by immunoprecipitation followed by immunoblotting ( Fig. 1f) .
We next used HEK 293 cells that separately express F8 FL or the protein products of the I22-inverted gene (F8 I22I and F8 B , respectively) in a transient expression system to test the ability of the monoclonal antibodies (mAbs) ab41188 and ESH8 to discriminate between FVIII I22I and FVIII B in a flow cytometry assay. The antibody ab41188 (specific to the A3 domain) detected FVIII FL and FVIII I22I but not FVIII B , whereas the antibody ESH8 (refs. 5-7) (specific to the C2 domain) detected FVIII FL and FVIII B but not FVIII I22I (Fig. 1g) . Furthermore, in all cell lines investigated, both mAbs showed a markedly greater fluorescence intensity in cells transfected with F8 FL compared to nontransfected negative control cells ( Supplementary Fig. 4a,b) . The detection of FVIII polypeptides was dose dependent with regard to the concentration of the F8 cDNA-containing expression vector used during transfection ( Supplementary Fig. 4c ). Using the FVIIIspecific mAbs ab41188 and GMA8006 (specific to the C2 domain), we also characterized the protein products of the F8 FL , F8 I22I and F8 B genes transfected into Huh-7 hepatic cells. As assessed on an immunoblot, and as expected, both mAbs identified FVIII FL , ab41188 identified FVIII I22I but not FVIII B, and GMA8006 identified FVIII B but not FVIII I22I (Fig. 1h) .
We used the flow cytometry assay validated above to detect FVIII polypeptides in permeabilized and nonpermeabilized Nor and Inv cells.
We observed only a minimal amount of FVIII reactivity in nonpermeabilized Nor or Inv cells using the mAbs ab41188 and ESH8 (data not shown). After permeabilization, the fluorescence signal using each of the FVIII-specific mAbs GMA8006, ESH8 and ab41188 was five-to tenfold higher compared to isotype control antibodies ( Fig. 1i and Supplementary Fig. 5a ). Statistical analysis of four independent experiments showed that the median fluorescence intensity (MFI) of Nor and Inv cells labeled with a mAb to bovine factor V (Bo-FV), used as another negative control, was comparable to that of cells labeled with isotype control antibodies, and cells labeled with the FVIII-specific mAbs showed a significantly greater fluorescence intensity compared to those labeled with Bo-FV-specific mAbs (P = 0.0003 to P < 0.0001) ( Supplementary Fig. 5b ). Similarly, we were able to detect FVIII in peripheral blood mononuclear cells (PBMCs) obtained from six individuals with I22-inverted F8 using ab41188, GMA8006 or ESH8 (Fig. 1j) . The MFI of cells labeled with a Bo-FV-specific antibody was not significantly greater than that of cells labeled with the isotype control antibody (one-sided unpaired t-test P = 0.1489). In contrast, the MFI values of cells labeled with mAbs ab41188, GMA8006 or ESH8 were significantly greater than those of cells labeled with the Bo-FV-specific antibody (P < 0.0001 for each of the three mAbs).
In addition to the results shown above demonstrating the specificity of the FVIII-specific mAbs in transient expression systems (Fig. 1g,h and Supplementary Fig. 4) , we demonstrated the specificity of these mAbs in detecting FVIII polypeptides in Nor and Inv cells using a SMARTpool F8-targeted siRNA in a knockdown experiment. Transfection with FVIII-specific (F8) but not scrambled nonspecific siRNA resulted in the almost complete disappearance of the F8 FL , F8 I22I and F8 B mRNAs ( Fig. 2a ) and a substantial decrease in the amount of FVIII FL , FVIII I22I and FVIII B proteins (Fig. 2b) . The FVIII protein signal dose-dependently decreased as a function of siRNA concentration (Fig. 2b) ; the highest concentration of siRNA reduced FVIII abundance by approximately 70%.
Confocal microscopic imaging of permeabilized Nor and Inv cells labeled with ab41188 or ESH8 and an Alexa Fluor 488-conjugated secondary antibody showed the presence of FVIII polypeptides in intracellular compartments (Fig. 2c) . In addition to using isotype control antibodies and a Bo-FV-specific antibody as negative controls, we used PBMCs from two subjects, each of whom harbored a large deletion in the F8 gene (exons 23-26) and in whom no FVIII activity or protein could be detected (data not shown). Permeabilized PBMCs from one of these subjects and a subject with the I22I mutation were labeled with ab41188, ESH8 and GMA8006 (Fig. 2d) . All three mAbs showed a markedly higher fluorescence signal in cells obtained from the individual with the I22I mutation than in cells from the subject with the large deletion. The results of flow cytometry assays on PBMCs obtained from four individuals with the I22I mutation (two with proximal inversions and two with distal inversions) and the two individuals with large deletions are summarized in Figure 2e . The MFI was significantly higher in PBMCs from subjects with the I22I mutation compared to PBMCs from subjects with large deletions when the cells were labeled with the mAbs ab41188, ESH8 or GMA8006 (one-sided unpaired t-test P = 0.0003, P = 0.0007 and P = 0.0007, respectively). There was no statistically significant difference in fluorescence intensity using the Bo-FV-specific antibody between cells from subjects with large deletions and those from subjects with the I22I mutation (either proximal or distal) (one-sided unpaired t-test P = 0.5036). Similarly, using confocal microscopy, we were able to detect FVIII protein in PBMCs from two subjects with the npg I22I mutation, but not in cells from a subject with the large deletion ( Fig. 2f) . Finally, to test our hypothesis that individuals with the I22I mutation synthesize but do not secrete the FVIII I22I or FVIII B polypeptides, we evaluated the intracellular and extracellular amounts of FVIII in the Nor and Inv cell lines. Whereas we detected FVIII FL in both the cell lysate and the extracellular medium of Nor cells, we detected FVIII I22I and FVIII B only in the cell lysate of Inv cells (Fig. 2g) .
Although F8 has long been known to be transcribed in lymphoid cells, as observed in analyses of lymph node and splenic tissues 8, 9 , most studies have found that the primary site of FVIII expression is the liver 9,10 , consistent with the observation that liver transplantation can be partially curative for hemophilia A 11, 12 . Immunofluorescencebased histological evaluation of tissue sections from the cirrhotic liver explanted from the subject with the I22I mutation whose cells were used to generate the Inv cell line (subject 1), as well as liver tissue sections from two additional subjects with the I22I (subjects 2 and 3; it is unknown whether they had the proximal or distal inversion), revealed diffuse cytoplasmic staining of hepatocytes and liver sinusoidal endothelial cells, whether using the GMA8006, ESH8 or ab41188 mAbs (Fig. 3a) . These findings are consistent with expression of both FVIII I22I and FVIII B in these samples. PBMCs from subjects 2 and 3 were collected at the time of liver transplantation. These cells showed intracellular expression of FVIII (Fig. 3b) . We obtained similar results from a histological examination of serial sections of the explanted liver of subject 1 using immunohistochemistry. ESH8-stained sections of the transplanted (normal) liver showed the presence of FVIII FL , FVIII B or both within the cytoplasm of both hepatocytes and liver sinusoidal endothelial cells (Fig. 3c, left) .
We observed a comparable staining pattern in the explanted liver from subject 1, presumably owing to the presence of FVIII B alone (Fig. 3c,  right) , given that the ESH8 epitope is located in the C2 domain, which is not present in FVIII I22I . Staining of the transplanted (normal) liver with ab41188, whose epitope resides within the A3 domain, showed that the FVIII FL protein was expressed by both hepatocytes and liver sinusoidal endothelial cells. The explanted liver from Subject 1 showed a similar pattern with more pronounced staining, presumably owing to enhanced expression of FVIII I22I alone.
The data presented above indicate that F8 I22I and F8 B direct the synthesis of the entire FVIII primary structure within two polypeptide chains, FVIII I22I and FVIII B . Because these results were derived from experiments performed on samples from a limited number of subjects, we evaluated mRNA expression from the two types of I22inverted F8 loci in additional samples. We detected the F8 I22I and F8 B transcripts in total RNA of peripheral blood from each of 25 unrelated subjects with the I22I mutation, four with the proximal inversion and 21 with the distal inversion (data not shown). As described below, this cohort comprised subjects who self-identified as African American. Moreover, based on results from cDNA sequencing, the 5′ and 3′ ends of the F8 I22I and F8 B transcripts in all 25 subjects (regardless of whether the inversion occurred at the proximal or distal sites) were identical to those observed in the Inv cells (data not shown).
Resequencing of all 26 exonic regions of the I22-inverted F8 in any given individual can identify the sets of foreign peptides that represent putative T cell epitopes contained in an FVIII molecule that is used as a therapeutic protein. For any subject with the I22I mutation, the set of 14 overlapping 15-mer peptides (derived from the sequence of the npg recombinant FVIII used as a therapeutic) that span Met2124 and Val2125, which are encoded by the last codon of exon 22 and the first codon of exon 23, respectively, would be considered to be 'foreign' (Supplementary Fig. 6 ). Moreover, an individual with the I22I mutation who was treated with an FVIII replacement protein would be exposed to additional sets of putative T cell epitopes if the FVIII protein was derived from an F8 haplotype that did not match the subject's or if the protein was a B domain-deleted (BDD) recombinant FVIII product.
For the 25 African-American individuals with hemophilia A with the I22I mutation, we obtained a history of their past FVIII protein infusions and lifetime inhibitor status. For each individual, we also sequenced the F8 gene to detect nonsynonymous polymorphisms. (a) Confocal immunofluorescence microscopy using the indicated mAbs specific to FVIII (green). Tissue sections were obtained from the explanted liver of the individual with the I22I mutation whose cells were used to generate the Inv cells (subject 1), his transplanted liver (normal) and explanted livers from two additional subjects with the I22I mutation (subjects 2 and 3). Blue, DAPI-stained nuclei in blue. Neg con, negative control samples stained with secondary antibody (see Online Methods) alone. (b) Confocal images of PBMCs that were obtained at the time of liver transplantation for subjects 2 and 3 (a) and stained with the indicated mAbs (green). Blue, DAPI-stained nuclei. (c) Immunohistochemistry of tissue sections from a normal liver after its transplantation into subject 1 (left) and the explanted liver from the same individual (right). Clockwise from top left: H&E staining, negative control (stained with only a horseradish peroxidase (HRP)-conjugated goat secondary antibody (2° Ab) to mouse IgG Fc), ab41188 staining and ESH8 staining. LSECs, liver sinusoidal endothelial cells; RBCs, red blood cells. The original magnification used for all histologic images is 400×; scale bars, 50 µm. npg This group of subjects had a distribution of polymorphisms comparable to that found in three previous reports [13] [14] [15] (Fig. 4a) . Similarly, when we sequenced 47 European-American subjects with hemophilia A (Fig. 4a) , it was clear that with typically sized hemophilia A studies, the European-American population cannot provide a sufficient number of individuals with the different F8 nonsynonymous polymorphisms to allow an adequately powered statistical analysis. Thus, selection of African-American subjects with the I22I mutation is a nonbiased way of identifying individuals with a larger distribution of such polymorphisms. We previously hypothesized that a mismatch between the endogenous FVIII synthesized by an individual with hemophilia A and the infused protein drug can be a risk factor for immunogenicity 14, 16, 17 . A workflow for analyzing personalized responses to FVIII infusions in the subpopulation of individuals with the I22I mutation is illustrated in Supplementary Figure 6 . We first used FVIII sequence information to determine all regions of potential mismatch between the endogenous and infused FVIII proteins. Sources of mismatch are as follows: (i) the region that spans the junction encoded by the exons 22 and 23 of all infused recombinant FVIII proteins; (ii) nonsynonymous polymorphic positions for which the drug's sequence differs from the subject's (in the case of plasma-derived FVIII products, we have assumed that protein from all four common haplotypes, H1, H2, H3 and H4, would be infused); and (iii) in the case of BBD recombinant FVII product infusion, the non-naturally occurring sequence of the linker region. We then identified, for each subject, all overlapping 15-mer peptides that span these mismatched positions and determined the total number of such foreign peptides. As all individuals in this subset carry the I22I mutation, we did not expect differences between individuals due to the hemophilia A-causing mutation itself. The FVIII I22I and FVIII B proteins encoded by the intron 22-inverted F8 locus are predicted to have the same amino acid sequences whether the inversion is distal or proximal. We evaluated the association between the numbers of foreign peptides to which an individual was potentially exposed and whether or not that subject developed inhibitors. A receiver operator characteristic (ROC) curve analysis ( Fig. 4b) showed that this measure is a reasonably good predictor of immunogenicity (AUC = 0.727, P = 0.012). Similarly, we found that the average number of foreign peptides was significantly greater in individuals who developed inhibitors than in those who did not (onesided unpaired t-test P = 0.0027) ( Fig. 4c) .
Foreign peptides are potential T cell epitopes; to elicit an immune response, these peptides must be presented by the individual's MHC-II repertoire 16, 18 . We therefore performed high-resolution genotyping of the structural locus encoding the HLA class II (HLA-II) protein DRB1 (HLA-DRB1) in all subjects and for each individual computed the affinity of all potential foreign peptides to the DRB1 proteins encoded by the individual's HLA-DRB1 alleles. Next, for each individual, we estimated the number of stable peptide-DRB1 complexes (that is, those with affinity ≤500 nM 19 ) that are likely to advance the immune response. ROC curve showed that the predictive value of this number (for inhibitor development) is better than the number based solely on the total number of foreign peptides (Fig. 4b , AUC = 0.890, P = 0.001 (compare to AUC = 0.727, P = 0.012; see above)). Similarly, the average number of peptide-HLA-II complexes significantly predicted inhibitor development (Fig. 4d , one-sided unpaired t-test P = 0.0001), and this measure outperformed the average number of foreign peptides (P = 0.0027, see above).
Our results, based on study of the subset of subjects with hemophilia A due to the I22 inversion, suggest that polymorphisms in the F8 gene of African-American subjects with hemophilia A could be a risk factor for immunogenicity, consistent with results from a previous report 14 . Larger data sets of genotyped and HLA-typed patients are likely to emerge in the next few years and will be useful in validating these findings. Similarly, the identification of peptides presented by MHC-II molecules derived from individuals with hemophilia A who have developed inhibitors may provide direct evidence for this hypothesis. Broadly, our findings are in accord with previous reports suggesting a higher incidence of inhibitors among African-American than among European-American individuals with hemophilia A 13, 14 .
We obtained additional support for this hypothesis from a larger group (n = 313) of subjects with hemophilia A for whom only race, the lifetime prevalence of inhibitors and I22I status are known. For this cohort, we separately analyzed subjects with the I22I mutation and subjects with all other F8 mutations. Among individuals with the I22I mutation, there was a statistically significant greater prevalence of both high-and low-titer inhibitors in black (n = 50) compared to European-American (n = 77) subjects (P = 0.052 and P = 0.017 for high-titer and high-plus low-titer inhibitors, respectively) (see Supplementary Fig. 7 and Online Methods). However, no statistically significant difference existed between the black (n = 85) and European-American (n = 101) populations in individuals who had mutations other than I22I (Supplementary Fig. 7) . These results further support the hypothesis that the greater underlying sequence diversity of black populations may be the driver for their higher prevalence of inhibitors.
Sequence diversity, in terms of single nucleotide polymorphisms, is consistent with the so-called serial founder effect, according to which the human species had a single origin in sub-Saharan Africa. Thus, a tree diagram depicting the migration of modern populations would show the sub-Saharan African populations at the root with sequential branches corresponding to North African, Middle Eastern, European, South or Central Asian, Oceanian, American and East Asian populations 20, 21 . The two populations we discuss in our study are almost at extreme ends of this tree and thus show sharp differences in sequence diversity, which in turn have clinical consequences. This suggests that the demographic and biological factors that have shaped human diversity could have important consequences in the practice of medicine and the development of new drugs.
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was mixed with 2× concentration of the SDS-PAGE loading buffer, heated at 100 °C for 10 min and diluted with an equal volume of water to bring the concentration to the loading buffer to 1×, followed by electrophoresis and western blot transfer to nitrocellulose. Blots were probed with purified polyclonal human factor VIII:C-specific sheep IgG (#CL20035A; 1:1,000). Following normal exposure, the blot was cut at the 36-kDa molecular weight marker (carbonic anhydrase in SeeBlue Plus2 Pre-Stained standard, cat. #LC5925, Invitrogen, NY). The signal in the lower part of the blot (<30 kDa) was developed and imaged by consecutively using chemiluminescent substrates of increasing sensitivity (SuperSignal West Pico (cat. #PI34080) or SuperSignal West Dura (cat. #PI34706), both from Thermo Scientific; PA, USA).
Identification of proteins in Coomassie blue-stained bands following SDS-PAGE. Human factor VIII-specific purified polyclonal sheep IgG (cat. #CL20035A; Cedarlane, NC, USA) were conjugated to Dynabeads Protein G (cat. #10003D, Invitrogen, NY, USA) at a ratio of 10 µg antibody per 50 ml of beads and used for immunoprecipitation of lysates of Nor and Inv cells and purified FVIII protein (Advate, Baxter; IL, USA). Coomassie blue-stained bands were subjected to in-gel trypsin digestion. Briefly, cysteines were reduced with dithiothreitol and alkylated with iodoacetamide 22 . Protein in the band was then digested with 13 ng µl −1 trypsin (Sigma) in 10 mM ammonium bicarbonate for 16 h at 30 °C. Peptides were then extracted by incubation in 50% acetonitrile, 10% trifluoroacetic acid for 10 min at 37 °C with shaking. The extraction was performed twice, followed by vacuum evaporation. The dried peptides were resuspended in water containing 2% acetonitrile, 0.5% acetic acid. They were then injected onto a 0.2 × 50 mm Magic C18AQ reverse-phase column (Michrom Bioresources; CA, USA) using the Paradigm MS4 HPLC (Michrom Bioresources; CA, USA). Peptides were separated at a flow rate of 2 µL min −1 , followed by online analysis by tandem mass spectrometry (MS/MS) using an LTQ ion-trap mass spectrometer (Thermo Scientific; PA, USA) equipped with an ADVANCE CaptiveSpray ion source (Michrom Bioresources; CA, USA). Peptides were eluted into the mass spectrometer using a linear gradient from 95% mobile phase A (2% acetonitrile, 0.5% acetic acid, 97.5% water) to 65% mobile phase B (10% water, 0.5% formic acid, 89.5% acetonitrile) over 20 min, followed by 95% mobile phase B over 5 min. Peptides were detected in positive ion mode using a data-dependent method, in which ions on a mass list derived from tryptic analysis of purified FVIII protein detected in an initial survey scan were selected for MS/MS analysis. The mass list is a list of parent ion masses (m/z) entered into the operating software. If the ions on the parent mass list were not detected in the survey screen, the most abundant ions were instead selected for MS/MS analysis. The MS/MS spectra were searched against the human database using TurboSEQUEST in BioWorks version 3.3.1 SP1 (ThermoElectron, San Jose, CA).
Southern blot analysis for I22I. Southern blot analysis was performed on genomic DNA samples extracted from either the Nor and Inv cells or EDTAanticoagulated blood specimens from the 25 African-American subjects with hemophilia A with the I22I mutation (collected at the time of their enrollment into the PATH study) using the QIAamp DNA Mini Kit or QIAamp DNA Blood Maxi Kit (QIAGEN; MD, USA), respectively, according to the manufacturer's instructions.
Confocal microscopy. Cells were grown overnight, harvested and washed 3× with PBS + 2% BSA. Fixation was performed in 4% paraformaldehyde (20 min at room temperature), followed by permeabilization with 0.2% Triton X-100 (5 min at room temperature). FVIII or FVIII domain-containing proteins were labeled using mAbs specific to different FVIII domains (see Fig. 3c for details) and detected using a secondary antibody specific to mouse IgG conjugated with Alexa Fluor 488. Nuclear counterstaining was performed with Vectashield mounting medium with DAPI (Vector Laboratories; CA, USA). Confocal images were acquired with Zeiss AM software on a Zeiss LSM 510 confocal microscope system (Carl Zeiss; NY, USA) with a Zeiss Axiovert 100M inverted microscope.
Knockdown of FVIII protein with siRNA. FVIII expression in lymphoblastoid cells (1 × 10 6 mL −1 ) was knocked down using SMARTpool FVIII-targeted siRNA (F8 Accell SMARTpool E-011032-00-005, Dharmacon; IL, USA) at a concentration of 1-4 µM in Accell medium using the Accell delivery system (Dharmacon). Scrambled nonspecific siRNA was used as a negative control (Accell siRNA control kit K-005000-G1-01, Dharmacon, IL, USA). F8 mRNA and FVIII protein levels were estimated using quantitative RT-PCR and flow cytometry, respectively, as described above.
